COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,722 Articles (22,502 medRxiv, 8,220 bioRxiv)

Most recent first Previous |  Page 134: Articles 1331-1340  | Next

Virological characteristics of the SARS-CoV-2 KP.3.1.1 variant
Kaku, Y., Uriu, K., Okumura, K., The Genotype to Phenotype Japan (G2P-Japan) Consortium, , Ito, J., Sato, K.
10.1101/2024.07.16.603835 — Posted: 2024-07-17
F-CPI: Prediction of activity changes induced by fluorine substitution using multimodal deep learning
Zhang, Q., Yin, W., Chen, X., Zhou, A., Zhang, G., Zhao, Z., Li, Z., Zhang, Y., Shen, J., Zhu, W., Jiang, X., Xu, Z.
10.1101/2024.07.17.602844 — Posted: 2024-07-17
Lower levels of household transmission of SARS-CoV-2 VOC Omicron compared to Wild-type: an interplay between transmissibility and immune status
Winkel, A., Kozanli, E., Haverkort, M., Euser, S., Sluiter-Post, J., Mariman, R., Vogelzang, A., de Bakker, J., Lap, C. R., van Houten, M., Eggink, D., van Lelyveld, S.
10.1101/2024.07.16.24310515 — Posted: 2024-07-16
Dissecting human monoclonal antibody responses from mRNA- and protein-based XBB.1.5 COVID-19 monovalent vaccines
Fantin, R., Clark, J., Cohn, H., Jaiswal, D., Bozarth, B., Civljak, A., Rao, V., Lobo, I., Nardulli, J., Srivastava, K., Yong, J., Andreata-Santos, R., Bushfield, K., Lee, E., Singh, G., Study group, P., Kleinstein, S., Krammer, F., Simon, V., Bajic, G., Coelho, C.
10.1101/2024.07.15.602781 — Posted: 2024-07-16
Functional implications of the interaction of the SARS-CoV-2 Nucleocapsid protein with factors involved in nonsense-mediated mRNA decay
Mallick, M., Boehm, V., Xue, G., Blackstone, M., Gehring, N. H., Chakrabarti, S.
10.1101/2024.07.16.603698 — Posted: 2024-07-16
The SARS-CoV-2 nucleocapsid protein inhibits the cellular Nonsense-Mediated mRNA Decay (NMD) pathway preventing the full enzymatic activation of UPF1.
Nuccetelli, V., Mghezzi-Habellah, M., Deymier, S., Roisin, A., Gerard-Baraggia, F., Rocchi, C., Coureux, P.-D., Gouet, P., Cimarelli, A., Mocquet, V., Fiorini, F.
10.1101/2024.07.16.603692 — Posted: 2024-07-16
SARS-CoV-2 entry and fusion are independent of ACE2 localization to lipid rafts
Bolland, W., Buchrieser, J., Schwartz, O., Casartelli, N., Porrot, F., Guivel-Benhassine, F., Marechal, I., Petiot, C.
10.1101/2024.07.13.603361 — Posted: 2024-07-16
Effect of the COVID-19 pandemic and maternal SARS-CoV-2 status on breastfeeding practices in the COMBO cohort
Walzer, L., Nichols, P., Amoo-Achampong, M. K., Glassman, M. E., Kyle, M. H., Hussain, M., Abreu, W., Scripps, T., Khan, A., Hanft, E., Xu, R. L., LoFrumento, M. A., Kataria, A., Stockwell, M. S., Dumitriu, D., Fernandez, C. R.
10.1101/2024.07.14.24309868 — Posted: 2024-07-15
Clinical and cost-effectiveness of diverse post-hospitalisation pathways for COVID-19: A UK evaluation utilising the PHOSP-COVID cohort
Briggs, A. H., A, I., Walters, A., Houchen-Wolloff, L., Armstrong, N., Emerson, T., Gill, R., Hastie, C., Little, P., Overton, C., Pimm, J., Poinasamy, K., Singh, S., Walker, S., Leavy, O., Richardson, M., Elneima, O., McAuley, H., Shikotra, A., Singapuri, A., Sereno, M., Saunders, R., Harris, V., Greening, N., Harrison, E., Docherty, A., Lone, N., Quint, J., Chalmers, J., Ho, L.-P., Horsley, A., Raman, B., Wain, L., Brightling, C., Marks, M.
10.1101/2024.07.15.24310151 — Posted: 2024-07-15
Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single center study.
Gentile, I., Viceconte, G., Cuccurullo, F., Pietroluongo, D., D'Agostino, A., Silvitelli, M., Mercinelli, S., Scotto, R., Grimaldi, F., Palmieri, S., Gravetti, A., Trastulli, F., Moccia, M., Buonomo, A. R.
10.1101/2024.07.15.24310384 — Posted: 2024-07-15

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).